ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
6.96
-0.33 (-4.53%)
At close: Apr 28, 2026, 4:00 PM EDT
7.03
+0.07 (1.01%)
After-hours: Apr 28, 2026, 5:57 PM EDT
ImmunityBio Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for ImmunityBio stock have an average target of 12.57, with a low estimate of 7.00 and a high estimate of 23. The average target predicts an increase of 80.60% from the current stock price of 6.96.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for ImmunityBio stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 5 | 5 | 5 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +230.46% | Apr 21, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +230.46% | Apr 8, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +230.46% | Mar 26, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +230.46% | Mar 23, 2026 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $23 | Strong Buy | Maintains | $23 | +230.46% | Mar 17, 2026 |
Financial Forecast
Revenue This Year
213.65M
from 113.29M
Increased by 88.59%
Revenue Next Year
493.86M
from 213.65M
Increased by 131.15%
EPS This Year
-0.26
from -0.38
EPS Next Year
-0.06
from -0.26
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 268.9M | 820.7M | ||||||
| Avg | 213.7M | 493.9M | ||||||
| Low | 169.0M | 277.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 137.4% | 284.1% | ||||||
| Avg | 88.6% | 131.2% | ||||||
| Low | 49.1% | 29.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.19 | 0.16 | ||||||
| Avg | -0.26 | -0.06 | ||||||
| Low | -0.31 | -0.26 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.